Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a Single Molecule

LEXINGTON, Mass., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
October 03, 2014 07:00 ET | Source: Curis, Inc.

Curis to Present at the 13th Annual BIO Investor Forum

LEXINGTON, Mass., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
October 02, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces CUDC-907 Development Program Advancements

-- Expansion cohorts opened to enroll patients with relapsed/refractory Diffuse Large B-Cell Lymphoma and Multiple Myeloma -- -- Second IND open for Curis to initiate additional clinical study in...
August 27, 2014 07:00 ET | Source: Curis, Inc.

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
August 07, 2014 07:00 ET | Source: Curis, Inc.

Curis Reports Second Quarter 2014 Financial Results

LEXINGTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
July 31, 2014 07:00 ET | Source: Curis, Inc.

Curis to Release Second Quarter 2014 Financial Results and Hold Conference Call on August 7, 2014

LEXINGTON, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
June 23, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase 2 Study of Erivedge(R) (vismodegib) in Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., June 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
June 18, 2014 07:00 ET | Source: Curis, Inc.

Curis to Present at the JMP Securities Healthcare Conference

LEXINGTON, Mass., June 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that the...
June 05, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces Re-Initiation of Patient Dosing in CUDC-427 Monotherapy Clinical Trial

LEXINGTON, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
June 03, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces Executive Management Transition

-- Ali Fattaey, Ph.D. Promoted to President and Chief Executive Officer -- -- Daniel Passeri Assumes Role of Vice Chairman, Curis Board of Directors and Strategic Advisor -- LEXINGTON, Mass.,...